Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism

Lawal et al report on a 45-fold increase in secondary hematologic malignancy in 120 patients following hematopoietic stem cell transplantation (HSCT) for sickle cell disease (SCD), comparable to what has been reported following gene therapy. Notably, the cohort is enriched for older patients and for...

Full description

Saved in:
Bibliographic Details
Published inBlood Vol. 140; no. 23; pp. 2514 - 2518
Main Authors Lawal, Rialnat A., Mukherjee, Devdeep, Limerick, Emily M., Coles, Wynona, Hsieh, Matthew M., Dillon, Laura W., Hourigan, Christopher S., Fitzhugh, Courtney D.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 08.12.2022
The American Society of Hematology
Subjects
Chimerism
Hematologic Neoplasms - epidemiology
Hematologic Neoplasms - therapy
Humans
Letter to Blood
Online AccessGet full text
ISSN0006-4971
1528-0020
1528-0020
DOI10.1182/blood.2022017960

Cover

More Information
Summary:Lawal et al report on a 45-fold increase in secondary hematologic malignancy in 120 patients following hematopoietic stem cell transplantation (HSCT) for sickle cell disease (SCD), comparable to what has been reported following gene therapy. Notably, the cohort is enriched for older patients and for haploidentical transplant recipients with mixed chimerism following HSCT. These data further support the idea that pre-existing premalignant myeloid clones undergo clonal selection in the setting of nonmyeloablative HSCT and contribute to secondary malignancy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
R.A.L. and D.M. contributed equally to the work.
L.W.D., C.S.H., and C.D.F. contributed equally to the work.
ISSN:0006-4971
1528-0020
1528-0020
DOI:10.1182/blood.2022017960